CT features of exophthalmos in Chinese subjects with thyroid-associated ophthalmopathy

被引:18
|
作者
Fang, Zhi-Jia [1 ]
Zhang, Jenny Y. [2 ]
He, Wei-Min [3 ]
机构
[1] Sichuan Univ, Dept Radiol, West China Hosp, Chengdu 610041, Sichuan Provinc, Peoples R China
[2] Univ Illinois, Chicago, IL 60607 USA
[3] Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu 610041, Sichuan Provinc, Peoples R China
关键词
thyroid-associated ophthalmopathy (TAO); computed tomography (CT); exophthalmos; GRAVES OPHTHALMOPATHY; DISEASE-ACTIVITY; ORBITOPATHY; PREDICTION; MUSCLES; MRI;
D O I
10.3980/j.issn.2222-3959.2013.02.07
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
AIM: To investigate computed tomography (CT) features of exophthalmos in Chinese subjects with thyroid-associated ophthalmopathy (TAO). METHODS: A total of 605 eyes of 325 patients with exophthalmos due to TAO were classified as grade I (mild exophthalmos) or II (severe exophthalmos) based on orbital CT imaging. The increased orbital volume features, such as changes from extraocular muscles, orbital fat, or both, were analyzed. RESULTS: A total of 605 eyes were analyzed, among them 62.98% presented grade I exophthalmos, while 36.02% showed grade II exophthalmos. In grade I, 56.69% showed orbital fat change, and in grade II, 89.29% exhibited extraocular muscle enlargement. CONCLUSION: Orbital fat and extraocular muscle enlargement are likely to be observed on CTs of subjects with mild and severe exophthalmos, respectively. Our results suggest that CT findings may guide TAO clinical therapy recommendations and prognosis.
引用
收藏
页码:146 / 149
页数:4
相关论文
共 50 条
  • [31] The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy
    Gould, Daniel J.
    Roth, Forrest S.
    Soparkar, Charles N. S.
    AESTHETIC PLASTIC SURGERY, 2012, 36 (03) : 638 - 648
  • [32] AZATHIOPRINE IN THE TREATMENT OF THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    WEIGHTMAN, DR
    CROMBIE, AL
    KENDALLTAYLOR, P
    ACTA ENDOCRINOLOGICA, 1990, 122 (01): : 8 - 12
  • [33] Animal models of thyroid-associated ophthalmopathy
    Ludgate, ME
    THYROID, 2002, 12 (03) : 205 - 208
  • [34] 2021 update on thyroid-associated ophthalmopathy
    Neag, E. J.
    Smith, T. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 235 - 259
  • [35] Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients
    Jang, S. Y.
    Lee, S. Y.
    Lee, E. J.
    Yoon, J. S.
    EYE, 2012, 26 (09) : 1263 - 1269
  • [36] Medical treatment for thyroid-associated ophthalmopathy
    Perros, P
    Kendall-Taylor, P
    THYROID, 2002, 12 (03) : 241 - 244
  • [37] Current management of thyroid-associated ophthalmopathy
    Kendall-Taylor, P
    CLINICAL ENDOCRINOLOGY, 1998, 49 (01) : 11 - 12
  • [38] PATHOGENETIC MECHANISMS IN THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    KENDALLTAYLOR, P
    JOURNAL OF INTERNAL MEDICINE, 1992, 231 (03) : 205 - 211
  • [39] Teprotumumab for thyroid-associated ophthalmopathy OPTIC
    Gaertner, R.
    Nitschmann, S.
    INTERNIST, 2020, 61 (11): : 1208 - 1210
  • [40] Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients
    S Y Jang
    S Y Lee
    E J Lee
    J S Yoon
    Eye, 2012, 26 : 1263 - 1269